Treatment
Etoposide clinical trials
We’re tracking 157 recruiting studies that include Etoposide, each written for real people, not researchers, below.
Recruiting studies
- NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT05681260RecruitingPhase 3
Methotrexate dose comparison for newly diagnosed T-cell lymphoma
This Phase 3 trial compares a higher dose of methotrexate versus an escalating (step-up) methotrexate plan in children newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see which dosing approach works better and is safe enough to use as standard treatment.
Shanghai, Shanghai MunicipalityAges 1–18 - NCT04696575RecruitingPhase 2
Lamivudine added to chemoimmunotherapy for extensive-stage lung cancer
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
Buffalo, New YorkAges 18 years+ - NCT04432714RecruitingPhase 1/Phase 2
Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Nanjing, JiangsuAges 18–60 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT02797717Recruiting
Treatment study for classical Hodgkin lymphoma in young people
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Petah TikvaAges 1 month–18 years - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT06262438RecruitingPhase 2
Quizartinib plus chemo for children with FLT3-ITD AML
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
Utrecht, UtrechtAges 1 month–18 years - NCT07268040RecruitingPhase 2
Study of SHR-7787 injection plus other cancer drugs for solid tumors
This trial is testing a new drug, SHR-7787, combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07109401RecruitingPhase 2
Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
ShanghaiAges 18–75 - NCT07227597RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced small cell lung cancer
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Santa Rosa, CaliforniaAges 18 years+ - NCT06377540RecruitingPhase 2
Pembrolizumab plus BEAM with stem cell transplant for Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Minneapolis, MinnesotaAges 18 years+ - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06030258RecruitingPhase 1/Phase 2
Study of IN10018 plus standard chemo for extensive-stage small cell lung cancer
This trial tests a new drug called IN10018 combined with standard chemotherapy (carboplatin and etoposide) and an immunotherapy (anti-PD-1/L1) for people with extensive-stage small cell lung cancer (ES-SCLC) who have not yet been treated. The goal is to see if adding IN10018 helps shrink tumors or slow the cancer's growth.
JinanAges 18–75 - NCT07481669RecruitingPhase 2
Stem cell transplant for lymphoma at high risk of brain relapse
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
Hangzhou, ZhejiangAges 18–70 - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT06483282RecruitingPhase 2
Study of immunotherapy plus targeted therapy and chemo before surgery for lung cancer
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
Hangzhou, ZhejiangAges 18–75 - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Birmingham, AlabamaAges 6 months–30 years - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06401330RecruitingPhase 3
Wilms tumor treatment study for children and young adults
This study is testing different treatments for children and young adults with a type of kidney cancer called Wilms tumor. The treatment you get depends on certain risk factors, like tumor stage and lab results. The goal is to give the right amount of treatment for each person's situation.
Birmingham, AlabamaAges Up to 30 years - NCT06188676RecruitingPhase 3
Nivolumab with chemotherapy for newly diagnosed PMBL
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
MoscowAges 18–70
Common questions
- Are there clinical trials studying Etoposide?
- Yes. Clin2 currently lists 157 recruiting studies that include Etoposide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Etoposide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Etoposide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Etoposide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.